Home> Products> comprehensive diabetes management plan

{ "products": [ { "_id": "6890aa548a215c65672372e1", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "EMPATECH LINA 25/5", "description": "EMPATECH LINA 25/5 is a pharmaceutical tablet containing a combination of two active ingredients: Empagliflozin 25MG and Linagliptin 5MG. This medication is designed to help manage blood sugar levels in adults with type 2 diabetes mellitus. The combination works through complementary mechanisms to improve glycemic control more effectively than either drug alone. Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that promotes the excretion of excess glucose through urine, while Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances insulin secretion and suppresses glucagon release, particularly after meals. EMPATECH LINA 25/5 is generally prescribed alongside a balanced diet and regular exercise to optimize blood sugar management and reduce the risk of diabetes-related complications such as kidney damage, neuropathy, and cardiovascular issues.\n\nWhat is EMPATECH LINA 25/5?\n\nEMPATECH LINA 25/5 is a prescription medication combining Empagliflozin (25MG) and Linagliptin (5MG) tablets used to manage type 2 diabetes. It helps control elevated blood sugar levels by using dual actions — the removal of glucose via kidneys and improving pancreatic hormone responses. This combination aims to achieve better and sustained glycemic control, often necessary for patients who have inadequate blood sugar control with other treatments.\n\nUses of EMPATECH LINA 25/5\n\nTo improve blood sugar control in adults with type 2 diabetes, particularly when monotherapy is insufficient.\n\nOften used as a second-line therapy after metformin or when metformin is not tolerated.\n\nTo reduce HbA1c (hemoglobin A1c), an important measure of long-term glucose control.\n\nMay help reduce weight and blood pressure as empagliflozin aids in glucose excretion.\n\nSupports comprehensive diabetes management along with diet and exercise.\n\nPrevents or reduces the risk of diabetes-associated complications such as kidney disease, cardiovascular events, and nerve damage.\n\nSide Effects of EMPATECH LINA 25/5\n\nCommon side effects may include urinary tract infections and genital infections due to increased glucose in urine.\n\nIncreased urination and dehydration.\n\nDizziness or lightheadedness, especially when standing up quickly.\n\nHypoglycemia (low blood sugar), though rare with this combination.\n\nGastrointestinal symptoms such as nausea or diarrhea.\n\nPotential increased risk of ketoacidosis (a serious condition related to high blood acids) in rare cases.\n\nAllergic reactions, although uncommon, may occur and require prompt medical attention.\n\nPrecautions Before Using EMPATECH LINA 25/5\n\nInform your healthcare provider if you have kidney disease, liver problems, or a history of urinary tract infections.\n\nNot recommended for type 1 diabetes or diabetic ketoacidosis treatment.\n\nUse with caution if you are pregnant, planning to become pregnant, or breastfeeding.\n\nStay hydrated while on this medication to reduce the risk of dehydration and dizziness.\n\nInform your doctor about any history of pancreatitis or pancreas disorders.\n\nRegular monitoring of kidney function and blood sugar levels is advised during treatment.\n\nAvoid drinking excessive alcohol as it may increase side effects or risk of ketoacidosis.\n\nDrug Interactions: What Drugs Interact with EMPATECH LINA 25/5?\n\nOther antidiabetic medications, such as insulin or sulfonylureas, may increase the risk of hypoglycemia.\n\nDiuretics, blood pressure medications, and lithium may interact and increase side effects.\n\nDrugs that impair kidney function can affect empagliflozin’s efficacy and safety.\n\nCertain enzyme-inducing drugs may reduce linagliptin levels, lowering its effectiveness.\n\nConsult your healthcare provider for a full list of possible interactions and before starting any new medication, including over-the-counter drugs or supplements.\n\nConclusion\n\nEMPATECH LINA 25/5, containing Empagliflozin 25MG and Linagliptin 5MG, is an effective combination medication to treat high blood sugar levels caused by type 2 diabetes. Its dual-action approach targets different physiological mechanisms to improve blood glucose control, helping reduce the risks and complications associated with diabetes. While it is generally well-tolerated, awareness of possible side effects and drug interactions is important. Always use under medical supervision, alongside lifestyle modifications such as diet and exercise, for optimal diabetes management.", "price": 345.0, "discountamount": 104.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2154, "imageuri": "https://productimages.withfloats.com/actual/6890aa58dd0bc098c3220f4c.png", "tileimageuri": "https://productimages.withfloats.com/tile/6890aa58dd0bc098c3220f4c.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-08-04T12:40:52.619Z", "updatedon": "2025-08-04T12:40:52.619Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empatech-lina-25-5/2154", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Empagliflozin and Linagliptin Tablets", "category": "DIABETIC RANGE", "tags": [ "Empagliflozin and Linagliptin Tablets" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "67a35767912e6c5ba00a1473", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Empagliflozin (5mg) ,Metformin Hydrochloride (500mg)", "description": "GLIEMPAFLOZIN MET is an advanced oral medication designed for the effective management of Type 2 Diabetes Mellitus. This combination of Empagliflozin (5mg) and Metformin Hydrochloride (500mg) helps regulate blood sugar levels, improve insulin sensitivity, and reduce the risk of diabetes-related complications. It is commonly prescribed as part of a comprehensive diabetes care plan, including diet and lifestyle modifications.\n\n \nKey Benefits:\n \n\nEffective Blood Sugar Control – Helps maintain stable blood glucose levels.\nReduces Insulin Resistance – Enhances the body's ability to utilize insulin efficiently.\nPromotes Weight Management – Empagliflozin aids in weight loss by eliminating excess glucose.\nImproves Cardiovascular Health – Lowers the risk of heart disease in diabetic patients.\nSupports Kidney Function – Helps reduce the progression of diabetic kidney disease.\nLower Risk of Hypoglycemia – Unlike some other diabetes medications, it has a lower risk of causing dangerously low blood sugar levels.\n \nHow Does It Work?\n \n\nGLIEMPAFLOZIN MET combines two powerful antidiabetic agents to provide synergistic effects:\n\nEmpagliflozin (SGLT2 Inhibitor): Blocks glucose reabsorption in the kidneys, allowing excess sugar to be excreted through urine. This helps lower blood glucose levels effectively.\nMetformin (Biguanide): Works by decreasing glucose production in the liver and improving insulin sensitivity, leading to better glucose utilization by body tissues.\nTogether, these mechanisms help in long-term diabetes management, reducing complications and improving overall well-being.\n\n \nDirections for Use:\n \n\nTake one tablet as prescribed by your healthcare provider.\nPreferably consume with meals to minimize stomach discomfort.\nSwallow the tablet whole with water; do not crush or chew.\nMaintain a healthy diet and exercise routine for optimal results.\nRegular blood sugar monitoring is recommended to track progress.\n \nSide Effects:\n \n\nWhile GLIEMPAFLOZIN MET is generally well-tolerated, some individuals may experience:\n\nCommon Side Effects:\n\nNausea, vomiting, or diarrhea\nIncreased urination\nMild dehydration\nWeakness or dizziness\nSerious Side Effects (Seek Medical Attention):\n\nKetoacidosis: Unusual fatigue, nausea, vomiting, or breathing difficulties.\nUrinary Tract Infections (UTIs): Burning sensation while urinating, fever, or pelvic pain.\nLactic Acidosis (Rare but Severe): Muscle pain, trouble breathing, irregular heartbeat.\nIf any severe reactions occur, consult a doctor immediately.", "price": 115.0, "discountamount": 35.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "lower risk", "healthy diet", "commonly prescribed", "doctor immediately", "urinating fever", "generally welltolerated", "gliempaflozin met", "exercise routine", "chew maintain", "wellbeing directions", "body tissues", "diabetes medications", "hypoglycemia unlike", "heart disease", "weight loss", "bodys ability", "diabetesrelated complications", "empagliflozin 5mg", "effective management", "glucose utilization", "decreasing glucose production", "powerful antidiabetic agents" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2043, "imageuri": "https://productimages.withfloats.com/actual/67a35783a4575f9364b319c7.png", "tileimageuri": "https://productimages.withfloats.com/tile/67a35783a4575f9364b319c7.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-02-05T12:19:51.149Z", "updatedon": "2025-03-22T10:21:42.769Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empagliflozin-5mg-metformin-hydrochloride-500mg-/2043", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIEMPAFLOZIN MET 5MG/ 500MG ", "category": "DIABETIC RANGE", "tags": [ "empagliflozin/metformin 5 mg/1000 mg", "empagliflozin + metformin combination brand name", "Empagliflozin and metformin hydrochloride tablets", "empagliflozin + metformin brand name in india", "empagliflozin 12.5 mg+metformin 500 mg price" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "67122bef263d0316fb4c9dcb", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Gliclazide IP (40 mg) , Pioglitazone Hydrochloride IP (15 mg) , Metformin Hydrochloride IP (500 mg)", "description": "TRI-GLICLAGLAZE 40 is a powerful oral anti-diabetic medication formulated to manage Type 2 Diabetes Mellitus effectively. This combination of three potent drugs—Gliclazide, Pioglitazone, and Metformin—works synergistically to control high blood sugar levels, improve insulin sensitivity, and help patients achieve better glycemic control. TRI-GLICLAGLAZE 40 is designed for patients who struggle to manage blood glucose levels with single medications or lifestyle changes alone. It is a comprehensive solution for long-term diabetes management and reducing the risk of complications related to uncontrolled blood sugar.\n\n \n\nKey Benefits:\n \n\nEffective Blood Sugar Control: TRI-GLICLAGLAZE 40 helps maintain optimal blood glucose levels by targeting different aspects of diabetes management, such as stimulating insulin release, improving insulin sensitivity, and reducing glucose production.\nReduces Insulin Resistance: Pioglitazone and Metformin work together to lower insulin resistance, making it easier for the body to use insulin effectively.\nImproves Long-Term Glycemic Control: By combining three active ingredients, this medication is particularly beneficial for those struggling with glycemic control through diet or monotherapy alone.\nReduces Risk of Diabetes Complications: Controlling blood sugar levels helps prevent diabetes-related complications such as nerve damage, kidney disease, and cardiovascular problems.\nSupports Weight Management: Metformin, in particular, has been known to assist with weight management, which is important for patients with Type 2 Diabetes.\n \n\nHow Does It Work?\n \nTRI-GLICLAGLAZE 40 works through a multi-faceted mechanism to lower blood glucose levels:\n\nGliclazide stimulates the beta cells in the pancreas to release more insulin, which lowers blood sugar levels post-meal.\n\nPioglitazone enhances the body's sensitivity to insulin by promoting glucose uptake in the muscle and fat cells while also decreasing glucose production in the liver.\n\nMetformin reduces the production of glucose in the liver and improves insulin sensitivity. It also decreases the absorption of sugar from the intestines, ensuring better blood sugar control throughout the day.\n\nThis combination of ingredients targets multiple pathways involved in glucose regulation, making it an effective option for individuals with Type 2 Diabetes who require more comprehensive blood sugar control.\n\n \n\nDirections for Use:\n \nTake TRI-GLICLAGLAZE 40 exactly as prescribed by your doctor.\nUsually, it is taken once or twice daily with meals to minimize gastrointestinal discomfort.\nSwallow the tablet whole with water—do not crush or chew the tablet.\nContinue following your diet and exercise plan alongside the medication to achieve optimal blood sugar control.\nDo not skip doses, and consult your healthcare provider if you miss a dose.\n \n\nSide Effects:\n \nLike any medication, TRI-GLICLAGLAZE 40 may cause side effects, although not everyone experiences them. Some common and mild side effects include:\n\nHypoglycemia (Low Blood Sugar): Due to Gliclazide’s insulin-stimulating properties, low blood sugar may occur, especially if meals are skipped or exercise is excessive.\n\nGastrointestinal Issues: Metformin is known to cause digestive problems in some individuals, including nausea, vomiting, diarrhea, or stomach cramps.\n\nWeight Gain: Pioglitazone may cause weight gain in some users due to increased fat storage.\n\nFluid Retention: Pioglitazone may lead to water retention, especially in patients with heart conditions, increasing the risk of heart failure.\n\nHeadache and dizziness: These may occur as the body adjusts to the medication, but they are generally mild and temporary.\n\nLactic Acidosis (rare): A serious but rare side effect of Metformin, this condition requires immediate medical attention and is characterized by muscle pain, breathing difficulties, and weakness.\n\n ", "price": 145.0, "discountamount": 43.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "fat cells", "beta cells", "muscle pain", "fat storage", "Weight Gain", "nerve damage", "Key Benefits", "exercise plan", "Gliclazide IP", "heart failure", "stomach cramps", "kidney disease", "glucose uptake", "water retention", "insulin release", "Lactic Acidosis", "Fluid Retention", "Low Blood Sugar", "heart conditions", "rare side effect", "multiple pathways", "different aspects", "lifestyle changes", "Weight Management", "mild side effects", "Insulin Resistance", "digestive problems", "single medications", "glucose production", "glucose regulation", "three potent drugs", "insulin sensitivity", "healthcare provider", "breathing difficulties", "Diabetes Complications", "comprehensive solution", "Metformin Hydrochloride", "Gastrointestinal Issues", "multi-faceted mechanism", "cardiovascular problems", "high blood sugar levels", "Type 2 Diabetes Mellitus", "three active ingredients", "uncontrolled blood sugar", "Long-Term Glycemic Control", "gastrointestinal discomfort", "immediate medical attention", "optimal blood sugar control", "optimal blood glucose levels", "Pioglitazone Hydrochloride IP", "long-term diabetes management", "Effective Blood Sugar Control", "diabetes-related complications", "insulin-stimulating properties", "comprehensive blood sugar control", "powerful oral anti-diabetic medication" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1994, "imageuri": "https://productimages.withfloats.com/actual/67122bf4ac30f07ce03345d7.png", "tileimageuri": "https://productimages.withfloats.com/tile/67122bf4ac30f07ce03345d7.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-10-18T09:35:43.008Z", "updatedon": "2024-10-18T09:35:43.008Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/gliclazide-ip-40-mg-pioglitazone-hydrochloride-ip-15-mg-metformin-hydrochloride-ip-500-mg-/1994", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRI - GLICLAGLAZE 40 ", "category": "DIABETIC RANGE", "tags": [ "gliclazide+metformin hydrochloride tablets uses", "Gliclazide Metformin Pioglitazone brand name", "Gliclazide and Metformin hydrochloride tablets Use", "Gliclazide and Metformin Hydrochloride tablets pri", "Gliclazide and Metformin Hydrochloride Tablets bra", "Gliclazide 80 mg and Metformin Hydrochloride table", "", "" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668e8611b9f7300708fe1240", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRIOGLIMITERIS 1/0.2 ", "description": "TRIOGLIMITERIS 1/0.2 \nVoglibose 0.2 mg, Glimepiride 1 mg & Metformin Hydrochloride 500 mg\nIntroduction\n\nTRIOGLIMITERIS 1/0.2 is a combination medication containing Voglibose, Glimepiride, and Metformin Hydrochloride. It is primarily used in the management of type 2 diabetes mellitus to improve glycemic control through different mechanisms of action targeting glucose metabolism.\n\nComposition\n\nVoglibose (0.2 mg): An alpha-glucosidase inhibitor that delays the digestion of carbohydrates in the intestine, thereby reducing postprandial blood glucose levels.\nGlimepiride (1 mg): A sulfonylurea derivative that stimulates insulin release from pancreatic beta cells, enhancing glucose uptake in peripheral tissues.\nMetformin Hydrochloride (500 mg): A biguanide that decreases hepatic glucose production, improves insulin sensitivity in peripheral tissues, and reduces intestinal glucose absorption.\nMechanism of Action\n\nTRIOGLIMITERIS 1/0.2 combines the actions of its components to achieve optimal glycemic control:\n\nVoglibose: Inhibits alpha-glucosidase enzymes in the intestine, delaying carbohydrate digestion and reducing the absorption of glucose after meals.\nGlimepiride: Stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner, thereby lowering blood glucose levels.\nMetformin Hydrochloride: Decreases hepatic glucose production through suppression of gluconeogenesis and enhances peripheral glucose uptake and utilization by improving insulin sensitivity.\nIndications\n\nTRIOGLIMITERIS 1/0.2 is indicated for:\n\nType 2 Diabetes Mellitus: Used to improve glycemic control in adults when diet, exercise, and monotherapy with metformin or sulfonylureas alone are not sufficient.\nDosage and Administration\n\nThe typical dosage of TRIOGLIMITERIS 1/0.2 is one tablet taken orally with meals, usually once or twice daily.\nDosage adjustments may be required based on individual patient response, blood glucose levels, and renal function.\nIt is essential to adhere to the prescribed dosage regimen to achieve optimal therapeutic outcomes.\nSide Effects\n\nCommon side effects of TRIOGLIMITERIS 1/0.2 may include:\n\nHypoglycemia (especially when used in combination with insulin or other antidiabetic medications)\nGastrointestinal disturbances (such as nausea, vomiting, diarrhea, or abdominal discomfort)\nWeight gain (mainly associated with sulfonylureas)\nMore severe side effects can include:\n\nAllergic reactions (rash, itching, swelling)\nLactic acidosis (rare but serious adverse effect associated with metformin use)\nHepatic dysfunction (monitor liver function tests periodically)\nPrecautions\n\nUse with caution in patients with renal impairment, hepatic dysfunction, or other significant medical conditions that may affect drug metabolism or excretion.\nRegular monitoring of blood glucose levels, renal function, and liver function is recommended during treatment with TRIOGLIMITERIS 1/0.2.\nAvoid use in patients with type 1 diabetes mellitus or diabetic ketoacidosis.\nDrug Interactions\n\nTRIOGLIMITERIS 1/0.2 may interact with other medications affecting blood glucose levels, such as insulin, other oral antidiabetic agents, or drugs that affect renal function or hepatic metabolism. Close monitoring and dose adjustments may be necessary.\nConclusion\n\nTRIOGLIMITERIS 1/0.2 provides a comprehensive approach to managing type 2 diabetes mellitus by combining Voglibose, Glimepiride, and Metformin Hydrochloride. This combination targets different aspects of glucose metabolism, enhancing insulin secretion, reducing hepatic glucose production, and delaying carbohydrate absorption in the intestine. Proper dosage, administration, and monitoring for side effects are essential to achieve and maintain optimal glycemic control in diabetic patients using TRIOGLIMITERIS 1/0.2. Consultation with a healthcare provider is recommended for personalized treatment plans and management of diabetes with this medication.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n", "price": 195.0, "discountamount": 58.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "500 mg", "0.2 mg", "one tablet", "Weight gain", "Glimepiride 1", "metformin use", "Proper dosage", "Glimepiride (1", "dosage regimen", "typical dosage", "renal function", "insulin release", "drug metabolism", "Lactic acidosis", "Close monitoring", "dose adjustments", "renal impairment", "diabetic patients", "insulin secretion", "different aspects", "Drug Interactions", "other medications", "Regular monitoring", "Dosage adjustments", "Allergic reactions", "peripheral tissues", "hepatic metabolism", "glucose metabolism", "insulin sensitivity", "healthcare provider", "Hepatic dysfunction", "Common side effects", "abdominal discomfort", "different mechanisms", "liver function tests", "diabetic ketoacidosis", "pancreatic beta cells", "combination medication", "carbohydrate digestion", "comprehensive approach", "serious adverse effect", "Metformin Hydrochloride", "carbohydrate absorption", "sulfonylurea derivative", "glucose-dependent manner", "optimal glycemic control", "type 1 diabetes mellitus", "type 2 diabetes mellitus", "More severe side effects", "alpha-glucosidase enzymes", "peripheral glucose uptake", "hepatic glucose production", "alpha-glucosidase inhibitor", "individual patient response", "personalized treatment plans", "optimal therapeutic outcomes", "Gastrointestinal disturbances", "intestinal glucose absorption", "other antidiabetic medications", "other oral antidiabetic agents", "postprandial blood glucose levels", "other significant medical conditions" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1939, "imageuri": "https://productimages.withfloats.com/actual/668e86143a68154e11e7d822.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e86143a68154e11e7d822.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T13:01:05.875Z", "updatedon": "2024-07-10T13:01:05.875Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trioglimiteris-1-0-2-/1939", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRIOGLIMITERIS 1/0.2 ", "category": "DIABETIC RANGE", "tags": [ "glimepiride 1mg+metformin 500mg+voglibose 0.2 mg", "Glimepiride 2mg Metformin 500mg Voglibose 0.2 mg b", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg", "voglibose glimepiride & metformin hydrochloride (s", "voglibose glimepiride + metformin hydrochloride us", "glimepiride 1mg+metformin 500mg+voglibose 0.3 mg", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg g", "" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6662cd3e870e7b20c49e689e", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VOGLIGOLD G3 M0.3 ", "description": "VOGLIGOLD G3 M0.3 \nVoglibose 0.3 mg, Glimepiride 3 mg & Metformin Hydrochloride 500 mg\nIntroduction to VOGLIGOLD G3 M0.3\nVOGLIGOLD G3 M0.3 is a combination medication designed for the effective management of type 2 diabetes mellitus. It contains three active ingredients: Voglibose 0.3mg, Glimepiride 3mg, and Metformin Hydrochloride 500mg. This multi-action formula targets different aspects of glucose regulation to provide comprehensive blood sugar control. It is used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Components and Their Mechanisms\nVoglibose 0.3mg\nVoglibose is an alpha-glucosidase inhibitor that works by:\n\nSlowing Carbohydrate Absorption: Voglibose inhibits the alpha-glucosidase enzyme in the small intestine, delaying the breakdown of complex carbohydrates into glucose. This helps to smooth out postprandial (after-meal) blood glucose peaks.\nGlimepiride 3mg\nGlimepiride is a sulfonylurea that helps control blood sugar by:\n\nStimulating Insulin Secretion: Glimepiride stimulates the pancreas to release more insulin, which helps lower blood sugar levels, particularly after meals.\nMetformin Hydrochloride 500mg\nMetformin is a biguanide that helps lower blood sugar levels through several mechanisms:\n\nReducing Hepatic Glucose Production: Metformin decreases the amount of glucose produced by the liver.\nImproving Insulin Sensitivity: It enhances the sensitivity of muscle cells to insulin, promoting better glucose uptake and utilization.\nDecreasing Intestinal Absorption of Glucose: Metformin reduces the absorption of glucose from the gastrointestinal tract.\nBenefits of VOGLIGOLD G3 M0.3\nComprehensive Blood Sugar Control\nFasting and Postprandial Glucose Management: The combination of Voglibose, Glimepiride, and Metformin effectively manages both fasting and postprandial blood sugar levels.\nEnhanced Insulin Secretion and Sensitivity: Glimepiride enhances insulin secretion, while Metformin improves insulin sensitivity, and Voglibose slows carbohydrate absorption.\nAdditional Health Benefits\nLow Risk of Hypoglycemia: The risk of hypoglycemia is minimized due to the complementary actions of the three components.\nWeight Neutrality: Metformin and Voglibose are generally weight neutral, making this combination favorable for patients concerned about weight gain associated with diabetes medications.\nHow to Use VOGLIGOLD G3 M0.3\nDosage and Administration\nRecommended Dosage: The typical dosage is one tablet taken once or twice daily, as prescribed by your healthcare provider.\nAdministration: Take the tablet with meals to reduce gastrointestinal side effects and enhance the absorption of Metformin. Swallow the tablet whole with a glass of water.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VOGLIGOLD G3 M0.3 regularly at the same time each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is essential to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vogligold-g3-m0-3-134319", "price": 185.0, "discountamount": 55.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "meal", "diet", "Order", "glass", "water", "EMAIL", "liver", "adults", "amount", "Fasting", "readings", "patients", "pancreas", "Low Risk", "exercise", "breakdown", "same time", "biguanide", "Decreasing", "one tablet", "Guidelines", "Glimepiride", "Adjustments", "weight gain", "information", "utilization", "Optimal Use", "best results", "Introduction", "sterispharma", "sulfonylurea", "Hypoglycemia", "muscle cells", "sterisonline", "CALL/WHATSAPP", "Voglibose 0.3", "Administration", "typical dosage", "glucose uptake", "treatment plan", "Consistent Use", "Key Components", "small intestine", "glycemic control", "three components", "VOGLIGOLD G3 M0.3", "different aspects", "Weight Neutrality", "several mechanisms", "glucose regulation", "Regular monitoring", "Recommended Dosage", "blood glucose peaks", "Insulin Sensitivity", "healthcare provider", "diabetes medications", "effective management", "multi-action formula", "complex carbohydrates", "Intestinal Absorption", "complementary actions", "gastrointestinal tract", "combination medication", "Metformin Hydrochloride", "Carbohydrate Absorption", "alpha-glucosidase enzyme", "three active ingredients", "type 2 diabetes mellitus", "Enhanced Insulin Secretion", "Additional Health Benefits", "Hepatic Glucose Production", "alpha-glucosidase inhibitor", "gastrointestinal side effects", "Postprandial Glucose Management", "postprandial blood sugar levels", "comprehensive blood sugar control" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1519, "imageuri": "https://productimages.withfloats.com/actual/667d30b6c303c6d6ad136ea4.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d30b6c303c6d6ad136ea4.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T09:05:02.904Z", "updatedon": "2024-06-27T09:28:16.215Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/vogligold-g3-m0-3-/1519", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VOGLIGOLD G3 M0.3 ", "category": "DIABETIC RANGE", "tags": [ "glimepiride 3mg+metformin 500mg+voglibose 0.3 mg", "voglibose glimepiride + metformin hydrochloride us", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6662c4c88ecffe165c354dc1", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VILDIABATE PIO ", "description": "VILDIABATE PIO \nVildagliptin 50 mg & Pioglitazone Hydrochloride 15 mg\nIntroduction to VILDIABATE PIO\nVILDIABATE PIO is a combination medication designed for the effective management of type 2 diabetes mellitus. It contains two active ingredients: Vildagliptin 50mg and Pioglitazone Hydrochloride 15mg. This dual-action formula targets different aspects of glucose regulation, providing comprehensive blood sugar control. It is used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Components and Their Mechanisms\nVildagliptin 50mg\nVildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that works by:\n\nEnhancing Incretin Levels: Vildagliptin inhibits the DPP-4 enzyme, which degrades incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). These hormones increase insulin secretion and decrease glucagon release in a glucose-dependent manner.\nImproving Postprandial Glucose Control: By enhancing the action of incretin hormones, Vildagliptin helps regulate blood sugar levels after meals.\nPioglitazone Hydrochloride 15mg\nPioglitazone is a thiazolidinedione that improves insulin sensitivity in muscle and adipose (fat) tissues. It works by:\n\nIncreasing Insulin Sensitivity: Pioglitazone enhances the body's response to insulin, allowing for better glucose uptake and utilization by cells.\nReducing Hepatic Glucose Production: Pioglitazone decreases the amount of glucose produced by the liver, helping to lower fasting blood sugar levels.\nBenefits of VILDIABATE PIO\nComprehensive Blood Sugar Control\nFasting and Postprandial Glucose Management: The combination of Vildagliptin and Pioglitazone effectively manages both fasting and postprandial (after-meal) blood sugar levels.\nImproved Insulin Sensitivity and Secretion: Vildagliptin enhances insulin secretion in response to meals, while Pioglitazone improves insulin sensitivity in peripheral tissues.\nAdditional Health Benefits\nLow Risk of Hypoglycemia: Vildagliptin has a low risk of causing hypoglycemia (low blood sugar) because it enhances insulin secretion only when blood glucose levels are elevated.\nCardioprotective Effects: Pioglitazone may provide additional cardiovascular benefits, such as improving lipid profiles and reducing inflammation, which can be beneficial for patients with diabetes who are at risk of cardiovascular diseases.\nWeight Management: While Pioglitazone may cause some weight gain due to fluid retention, Vildagliptin is generally weight neutral, balancing the overall effect on body weight.\nDosage and Administration\nRecommended Dosage\nDosage: The typical dosage of VILDIABATE PIO is one tablet taken once daily, preferably with a meal to enhance absorption and reduce gastrointestinal side effects.\nAdministration: Swallow the tablet whole with a glass of water. Do not crush, chew, or split the tablet unless advised by your healthcare provider.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VILDIABATE PIO regularly at the same time each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is essential to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vildiabate-pio-134257\n", "price": 295.0, "discountamount": 88.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "GIP", "diet", "Order", "meals", "EMAIL", "cells", "liver", "water", "glass", "GLP-1", "amount", "muscle", "adults", "Fasting", "adipose", "patients", "Low Risk", "exercise", "readings", "response", "Enhancing", "same time", "one tablet", "Mechanisms", "Increasing", "Guidelines", "absorption", "utilization", "Optimal Use", "information", "body weight", "Adjustments", "weight gain", "DPP-4 enzyme", "inflammation", "Introduction", "Vildagliptin", "Hypoglycemia", "sterispharma", "best results", "fat) tissues", "sterisonline", "CALL/WHATSAPP", "Administration", "VILDIABATE PIO", "glucose uptake", "Key Components", "Consistent Use", "treatment plan", "overall effect", "lipid profiles", "typical dosage", "Incretin Levels", "low blood sugar", "fluid retention", "glycemic control", "glucagon release", "DPP-4) inhibitor", "Weight Management", "insulin secretion", "incretin hormones", "different aspects", "thiazolidinedione", "peripheral tissues", "glucose regulation", "Regular monitoring", "healthcare provider", "dual-action formula", "insulin sensitivity", "blood glucose levels", "effective management", "dipeptidyl peptidase-4", "two active ingredients", "combination medication", "cardiovascular diseases", "Cardioprotective Effects", "type 2 diabetes mellitus", "meal) blood sugar levels", "glucose-dependent manner", "Recommended Dosage Dosage", "Pioglitazone Hydrochloride", "Additional Health Benefits", "Hepatic Glucose Production", "gastrointestinal side effects", "Postprandial Glucose Management", "comprehensive blood sugar control", "additional cardiovascular benefits", "Improving Postprandial Glucose Control", "glucose-dependent insulinotropic peptide" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1512, "imageuri": "https://productimages.withfloats.com/actual/667d3d8c5443982e2f655655.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d3d8c5443982e2f655655.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T08:28:56.298Z", "updatedon": "2024-06-27T10:23:02.274Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/vildiabate-pio-/1512", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VILDIABATE PIO ", "category": "DIABETIC RANGE", "tags": [ "vildagliptin metformin hydrochloride tablets uses", "vildagliptin + metformin + glimepiride combination", "vildagliptin 50 mg side effects", "vildagliptin and pioglitazone hydrochloride" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6662af26db100e1fdc2dcc17", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VILDIABATE M 1000 ", "description": "VILDIABATE M 1000 \nMetformin (1000mg)SR, Vildagliptin (50mg)\nIntroduction to VILDIABATE M 1000\nVILDIABATE M 1000 is a combination medication designed for the effective management of type 2 diabetes mellitus. It contains Metformin Hydrochloride Sustained Release (SR) 1000mg and Vildagliptin 50mg. This dual-action formula targets different pathways involved in glucose regulation to provide comprehensive blood sugar control. It is used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Components and Their Mechanisms\nMetformin SR 1000mg\nMetformin is a biguanide that helps lower blood sugar levels through several mechanisms:\n\nReduces Hepatic Glucose Production: Metformin decreases the amount of glucose produced by the liver.\nImproves Insulin Sensitivity: It enhances the sensitivity of muscle cells to insulin, promoting better glucose uptake and utilization.\nDecreases Intestinal Absorption of Glucose: Metformin reduces the absorption of glucose from the gastrointestinal tract.\nThe sustained release (SR) formulation ensures a gradual release of the medication, providing prolonged therapeutic effects and reducing the risk of gastrointestinal side effects.\n\nVildagliptin 50mg\nVildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that works by:\n\nEnhancing Incretin Levels: Vildagliptin inhibits the DPP-4 enzyme, which degrades incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). These hormones increase insulin secretion and decrease glucagon release in a glucose-dependent manner.\nImproving Postprandial Glucose Control: By enhancing the action of incretin hormones, Vildagliptin helps regulate blood sugar levels after meals.\nBenefits of VILDIABATE M 1000\nComprehensive Blood Sugar Control\nFasting and Postprandial Glucose Management: The combination of Metformin SR and Vildagliptin effectively manages both fasting and postprandial (after-meal) blood sugar levels.\nImproved Insulin Sensitivity and Secretion: Metformin improves insulin sensitivity, while Vildagliptin enhances insulin secretion in response to meals.\nExtended Release Formulation\nProlonged Effect: The sustained-release formulation of Metformin ensures a steady release of the medication, providing long-lasting blood sugar control and minimizing peaks and troughs in blood sugar levels.\nReduced Gastrointestinal Side Effects: The gradual release of Metformin helps reduce common gastrointestinal side effects associated with immediate-release formulations.\nAdditional Health Benefits\nLow Risk of Hypoglycemia: Vildagliptin, in particular, has a low risk of causing hypoglycemia (low blood sugar) because it enhances insulin secretion only when blood glucose levels are elevated.\nWeight Neutral: This combination is generally weight neutral, making it a suitable option for patients concerned about weight gain.\nDosage and Administration\nRecommended Dosage\nDosage: The typical dosage is one tablet taken once daily, preferably with a meal to reduce gastrointestinal side effects.\nAdministration: Swallow the tablet whole with a glass of water. Do not crush, chew, or split the tablet unless advised by your healthcare provider.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VILDIABATE M 1000 regularly at the same time each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is essential to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vildiabate-m-1000-133453", "price": 319.0, "discountamount": 95.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "GIP", "diet", "GLP-1", "Order", "EMAIL", "water", "glass", "liver", "peaks", "meals", "adults", "amount", "option", "troughs", "Fasting", "exercise", "Low Risk", "patients", "response", "readings", "same time", "Enhancing", "biguanide", "one tablet", "Guidelines", "Optimal Use", "information", "utilization", "weight gain", "Adjustments", "Introduction", "Vildagliptin", "Metformin SR", "VILDIABATE M", "sterispharma", "best results", "Hypoglycemia", "sterisonline", "DPP-4 enzyme", "muscle cells", "CALL/WHATSAPP", "Weight Neutral", "Consistent Use", "Administration", "treatment plan", "steady release", "typical dosage", "Key Components", "glucose uptake", "low blood sugar", "Incretin Levels", "gradual release", "SR) formulation", "glucagon release", "glycemic control", "Prolonged Effect", "DPP-4) inhibitor", "insulin secretion", "incretin hormones", "several mechanisms", "different pathways", "glucose regulation", "Regular monitoring", "dual-action formula", "healthcare provider", "Insulin Sensitivity", "blood glucose levels", "effective management", "Intestinal Absorption", "gastrointestinal tract", "combination medication", "dipeptidyl peptidase-4", "type 2 diabetes mellitus", "glucose-dependent manner", "meal) blood sugar levels", "Recommended Dosage Dosage", "Additional Health Benefits", "Hepatic Glucose Production", "Extended Release Formulation", "sustained-release formulation", "prolonged therapeutic effects", "immediate-release formulations", "Postprandial Glucose Management", "long-lasting blood sugar control", "comprehensive blood sugar control", "common gastrointestinal side effects", "Reduced Gastrointestinal Side Effects", "Improving Postprandial Glucose Control", "glucose-dependent insulinotropic peptide", "Metformin Hydrochloride Sustained Release" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1496, "imageuri": "https://productimages.withfloats.com/actual/6662af29d878d473a9fda03d.png", "tileimageuri": "https://productimages.withfloats.com/tile/6662af29d878d473a9fda03d.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T06:56:38.67Z", "updatedon": "2024-06-28T11:39:06.99Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/vildiabate-m-1000-/1496", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VILDIABATE M 1000 ", "category": "DIABETIC RANGE", "tags": [ "VILDIABATE M 1000", "Metformin (1000mg)SR", "Vildagliptin (50mg)", "Vildagliptin 50mg side effects", "Vildagliptin tablets 50 mg uses", "Vildagliptin 50 mg price", "Vildagliptin 50 mg and metformin 500 mg" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6661ac5887f0960e14a2c914", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TENELIGOLD M 500 ", "description": "TENELIGOLD M 500 \nMetformin SR (500mg), Teneligliptin (20mg)\nTENELIGOLD M 500 is a combination medication containing Metformin Hydrochloride Sustained Release (SR) 500mg and Teneligliptin 20mg. It is primarily prescribed for the management of type 2 diabetes mellitus, a condition characterized by high blood sugar levels due to insulin resistance or inadequate insulin production.\n\nMetformin SR 500mg is a widely used oral antidiabetic medication that belongs to the biguanide class. It works by reducing the amount of glucose produced by the liver, increasing insulin sensitivity in muscle cells, and improving glucose uptake by tissues. This helps lower blood sugar levels and improves glycemic control.\n\nTeneligliptin 20mg is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It enhances insulin secretion from pancreatic beta cells and inhibits glucagon secretion, leading to reduced blood glucose levels after meals. By targeting different pathways in glucose metabolism, Teneligliptin complements the action of Metformin, resulting in better overall glycemic control.\n\nBenefits of TENELIGOLD M 500:\nComprehensive Glycemic Control: The combination of Metformin and Teneligliptin addresses both fasting and postprandial (after-meal) blood sugar levels, providing comprehensive glycemic control throughout the day.\n\nImproved Insulin Sensitivity: Metformin improves insulin sensitivity in cells, allowing better utilization of glucose and reducing insulin resistance.\n\nEnhanced Incretin Effect: Teneligliptin enhances the incretin effect, which regulates insulin secretion and glucagon levels, leading to better glucose regulation.\n\nWeight Management: Metformin is associated with weight neutrality or modest weight loss, making it beneficial for overweight or obese individuals with diabetes.\n\nLow Risk of Hypoglycemia: The risk of hypoglycemia (low blood sugar) with TENELIGOLD M 500 is low when used appropriately, making it a safer option for many patients.\n\nHow to Use TENELIGOLD M 500:\nDosage: The typical dosage is one tablet taken orally once or twice daily, as directed by your healthcare provider. Dosage adjustments may be made based on blood sugar levels and individual response.\n\nAdministration: Take the tablet with meals to reduce gastrointestinal side effects and enhance absorption. Swallow it whole with a glass of water, and do not crush or chew the tablet unless advised otherwise.\n\nSafety Considerations:\nMedical History: Inform your doctor about any medical conditions you have, especially kidney or liver problems, as well as any medications or supplements you are taking.\n\nPregnancy and Nursing: Discuss the risks and benefits of TENELIGOLD M 500 if you are pregnant, planning pregnancy, or breastfeeding.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/teneligold-m-500-133449", "price": 122.75, "discountamount": 36.83, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "day", "Order", "meals", "glass", "risks", "water", "EMAIL", "action", "option", "amount", "kidney", "doctor", "fasting", "reduced", "tissues", "Nursing", "Low Risk", "Benefits", "Pregnancy", "absorption", "overweight", "one tablet", "medications", "supplements", "utilization", "information", "TENELIGOLD M", "Hypoglycemia", "muscle cells", "sterispharma", "postprandial", "sterisonline", "many patients", "breastfeeding", "CALL/WHATSAPP", "typical dosage", "Administration", "liver problems", "glucose uptake", "low blood sugar", "Medical History", "glucagon levels", "biguanide class", "DPP-4) inhibitor", "Weight Management", "weight neutrality", "obese individuals", "insulin secretion", "glucose regulation", "modest weight loss", "Metformin SR 500mg", "glucose metabolism", "insulin resistance", "glucagon secretion", "different pathways", "Teneligliptin 20mg", "Dosage adjustments", "medical conditions", "insulin sensitivity", "healthcare provider", "individual response", "blood glucose levels", "Safety Considerations", "pancreatic beta cells", "combination medication", "dipeptidyl peptidase-4", "high blood sugar levels", "overall glycemic control", "Enhanced Incretin Effect", "meal) blood sugar levels", "type 2 diabetes mellitus", "oral antidiabetic medication", "gastrointestinal side effects", "inadequate insulin production", "Comprehensive Glycemic Control", "Metformin Hydrochloride Sustained Release" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1479, "imageuri": "https://productimages.withfloats.com/actual/6661ac5c4b296a211c2d34ee.jpg", "tileimageuri": "https://productimages.withfloats.com/tile/6661ac5c4b296a211c2d34ee.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T12:32:24.912Z", "updatedon": "2024-06-29T05:26:50.914Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/teneligold-m-500-/1479", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TENELIGOLD M 500 ", "category": "DIABETIC RANGE", "tags": [ "TENELIGOLD M 500", "Metformin SR (500mg)", "Teneligliptin (20mg)", "Teneligliptin Tablets 20 mg uses", "Teneligliptin 20 mg price", "Teneligliptin 20 mg side effects" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6661a9f67247ae19c482a99a", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TENELIGOLD M 1000 ", "description": "TENELIGOLD M 1000 \nMetformin SR (1000mg), Teneligliptin (20mg)\nIntroduction to TENELIGOLD M 1000\nTENELIGOLD M 1000 is a combination medication that includes Metformin Hydrochloride Sustained Release (SR) 1000mg and Teneligliptin 20mg. This medication is primarily used for the management of type 2 diabetes mellitus. By combining the complementary mechanisms of Metformin and Teneligliptin, TENELIGOLD M 1000 offers comprehensive glycemic control, helping patients effectively manage their blood sugar levels.\n\nWhat are Metformin and Teneligliptin?\nOverview of Metformin\nMetformin is a biguanide that helps lower blood sugar levels by improving the body's sensitivity to insulin and reducing the amount of glucose produced by the liver. It also enhances peripheral glucose uptake and utilization. The sustained-release formulation ensures a prolonged effect throughout the day.\n\nOverview of Teneligliptin\nTeneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that helps control blood sugar levels by enhancing the body's ability to regulate insulin after meals. It works by inhibiting the DPP-4 enzyme, which results in prolonged activity of incretin hormones that play a significant role in glucose metabolism.\n\nBenefits of TENELIGOLD M 1000\nEffective Blood Sugar Management\nDual Mechanism of Action: Metformin improves insulin sensitivity and reduces hepatic glucose production, while Teneligliptin enhances insulin release and reduces glucagon levels after meals, providing comprehensive glycemic control.\nPostprandial and Fasting Glucose Control: This combination helps manage both postprandial (after-meal) and fasting blood sugar levels, offering all-around glycemic control.\nSupport for Diabetes Management\nDiet and Exercise Adjunct: TENELIGOLD M 1000 is an excellent adjunct to diet and exercise, helping patients achieve better blood sugar control when lifestyle modifications alone are insufficient.\nReduced Risk of Complications: By maintaining more stable blood sugar levels, this medication can help reduce the risk of long-term complications associated with diabetes, such as cardiovascular disease, neuropathy, and retinopathy.\nAdditional Health Benefits\nWeight Management: Metformin is often associated with weight neutrality or modest weight loss, making it a favorable option for overweight or obese patients.\nLow Risk of Hypoglycemia: When used alone or in combination with Metformin, Teneligliptin has a low risk of causing hypoglycemia compared to some other diabetes medications.\nHow to Use TENELIGOLD M 1000\nDosage and Administration\nRecommended Dosage: The typical dosage of TENELIGOLD M 1000 is one tablet taken once or twice daily, depending on your healthcare provider's instructions. The dosage may be adjusted based on individual response and blood sugar levels.\nAdministration: Take the tablet with meals to reduce the risk of gastrointestinal discomfort and enhance the effectiveness of Metformin. Swallow the tablet whole with a full glass of water.\nGuidelines for Optimal Use\nConsistent Use: For best results, take TENELIGOLD M 1000 regularly as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regularly check your blood sugar levels to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/teneligold-m-1000-133448", "price": 144.0, "discountamount": 43.2, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "day", "body", "Diet", "Order", "EMAIL", "liver", "water", "meals", "Action", "amount", "option", "ability", "Support", "Overview", "Low Risk", "readings", "biguanide", "one tablet", "full glass", "overweight", "neuropathy", "Guidelines", "information", "retinopathy", "utilization", "Adjustments", "Optimal Use", "instructions", "Hypoglycemia", "Introduction", "Metformin SR", "Postprandial", "sterispharma", "Reduced Risk", "TENELIGOLD M", "best results", "sterisonline", "DPP-4 enzyme", "Teneligliptin", "effectiveness", "CALL/WHATSAPP", "typical dosage", "treatment plan", "Administration", "Consistent Use", "Dual Mechanism", "obese patients", "glucagon levels", "insulin release", "DPP-4) inhibitor", "Exercise Adjunct", "prolonged effect", "significant role", "weight neutrality", "excellent adjunct", "Weight Management", "incretin hormones", "prolonged activity", "glucose metabolism", "Recommended Dosage", "modest weight loss", "Diabetes Management", "blood sugar control", "insulin sensitivity", "healthcare provider", "individual response", "dipeptidyl peptidase-4", "combination medication", "cardiovascular disease", "lifestyle modifications", "long-term complications", "Fasting Glucose Control", "type 2 diabetes mellitus", "complementary mechanisms", "peripheral glucose uptake", "stable blood sugar levels", "other diabetes medications", "Additional Health Benefits", "hepatic glucose production", "gastrointestinal discomfort", "sustained-release formulation", "comprehensive glycemic control", "Effective Blood Sugar Management", "Metformin Hydrochloride Sustained Release" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1476, "imageuri": "https://productimages.withfloats.com/actual/6661aa01a771049a81dc9ef8.png", "tileimageuri": "https://productimages.withfloats.com/tile/6661aa01a771049a81dc9ef8.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T12:22:14.966Z", "updatedon": "2024-06-28T12:38:50.531Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//teneligold-m-1000-/1476", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TENELIGOLD M 1000 ", "category": "DIABETIC RANGE", "tags": [ "TENELIGOLD M 1000", "Metformin SR (1000mg)", "Teneligliptin (20mg)", "Metformin SR 1000 mg uses", "Metformin SR 1000 mg side effects", "Metformin SR 1000 Mg Uses in Hindi", "Metformin SR 1000 price" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }